These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21575037)

  • 21. Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.
    Ma C; Zhang Y; Xu Q; Yang J; Zhang Y; Gao L; Xu B; Wang H; Li Y; Lu C; Yin T
    Int J Hematol; 2012 Dec; 96(6):719-28. PubMed ID: 23104259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding the pharmacogenetic approach to warfarin dosing.
    Glurich I; Burmester JK; Caldwell MD
    Heart Fail Rev; 2010 May; 15(3):239-48. PubMed ID: 18998206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.
    Biss TT; Avery PJ; Brandão LR; Chalmers EA; Williams MD; Grainger JD; Leathart JB; Hanley JP; Daly AK; Kamali F
    Blood; 2012 Jan; 119(3):868-73. PubMed ID: 22010099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.
    Shahin MH; Khalifa SI; Gong Y; Hammad LN; Sallam MT; El Shafey M; Ali SS; Mohamed ME; Langaee T; Johnson JA
    Pharmacogenet Genomics; 2011 Mar; 21(3):130-5. PubMed ID: 21228733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No.
    Mannucci PM; Spreafico M; Peyvandi F
    J Thromb Haemost; 2008 Sep; 6(9):1450-2. PubMed ID: 18627441
    [No Abstract]   [Full Text] [Related]  

  • 26. A randomized controlled trial of genotype-based Coumadin initiation.
    Burmester JK; Berg RL; Yale SH; Rottscheit CM; Glurich IE; Schmelzer JR; Caldwell MD
    Genet Med; 2011 Jun; 13(6):509-18. PubMed ID: 21423021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
    Daly AK
    Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenomic testing for warfarin dosing: we are ready now.
    Wu AH
    Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1483-5. PubMed ID: 19954308
    [No Abstract]   [Full Text] [Related]  

  • 29. Pathology consultation on warfarin pharmacogenetic testing.
    Stack G;
    Am J Clin Pathol; 2011 Jan; 135(1):13-9. PubMed ID: 21173120
    [No Abstract]   [Full Text] [Related]  

  • 30. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
    Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
    Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Warfarin pharmacogenetics: ready for clinical utility?
    Baudhuin LM
    Clin Lab Sci; 2009; 22(3):151-5. PubMed ID: 19827409
    [No Abstract]   [Full Text] [Related]  

  • 32. Genetic and clinical determinants influencing warfarin dosing in children with heart disease.
    Nguyen N; Anley P; Yu MY; Zhang G; Thompson AA; Jennings LJ
    Pediatr Cardiol; 2013 Apr; 34(4):984-90. PubMed ID: 23183958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese.
    Cha PC; Mushiroda T; Takahashi A; Kubo M; Minami S; Kamatani N; Nakamura Y
    Hum Mol Genet; 2010 Dec; 19(23):4735-44. PubMed ID: 20833655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
    Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
    Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenomics of warfarin dose requirements in Hispanics.
    Cavallari LH; Momary KM; Patel SR; Shapiro NL; Nutescu E; Viana MA
    Blood Cells Mol Dis; 2011 Feb; 46(2):147-50. PubMed ID: 21185752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C9*3/*3 genotypes.
    Fukuda T; Tanabe T; Ohno M; Tougou K; Fujio Y; Azuma J; Yamamoto I; Takeda A
    Clin Pharmacol Ther; 2006 Nov; 80(5):553-4. PubMed ID: 17112813
    [No Abstract]   [Full Text] [Related]  

  • 37. Warfarin anticoagulation in children: is there a role for a personalized approach to dosing?
    Biss TT; Kamali F
    Pharmacogenomics; 2012 Aug; 13(11):1211-4. PubMed ID: 22920389
    [No Abstract]   [Full Text] [Related]  

  • 38. Warfarin monitoring woes: a glimmer of hope with pharmacogenomics.
    Beier MT
    J Am Med Dir Assoc; 2008 Mar; 9(3):199-200. PubMed ID: 18294604
    [No Abstract]   [Full Text] [Related]  

  • 39. Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation.
    Xu Q; Xu B; Zhang Y; Yang J; Gao L; Zhang Y; Wang H; Lu C; Zhao Y; Yin T
    Thromb Haemost; 2012 Dec; 108(6):1132-40. PubMed ID: 23015069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.
    Scott SA; Khasawneh R; Peter I; Kornreich R; Desnick RJ
    Pharmacogenomics; 2010 Jun; 11(6):781-91. PubMed ID: 20504253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.